Akanda (NASDAQ:AKAN – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.
Separately, Weiss Ratings lowered shares of Akanda from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on AKAN
Akanda Price Performance
Akanda (NASDAQ:AKAN – Get Free Report) last posted its quarterly earnings results on Tuesday, June 9th. The company reported ($317.90) EPS for the quarter.
Akanda Company Profile
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Further Reading
- Five stocks we like better than Akanda
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Akanda Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akanda and related companies with MarketBeat.com's FREE daily email newsletter.
